Lack of T-cell receptor-induced signaling is crucial for CD95 ligand up-regulation and protects cutaneous T-cell lymphoma cells from activation-induced cell death

Cancer Research

Volumn 69, Issue 10, 2009, Pages 4175-4183

  Klemke, Claus Detlev ^a,b   Brenner, Dirk ^a,c   Weiß, Eva Maria ^a   Schmidt, Marc ^b   Leverkus, Martin ^d   Gülow, Karsten ^a   Krammer, Peter H ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; FLICE INHIBITORY PROTEIN; REACTIVE OXYGEN METABOLITE; T LYMPHOCYTE RECEPTOR;

ARTICLE; CALCIUM TRANSPORT; CANCER CELL; CANCER CELL CULTURE; CELL ACTIVATION; CELL DEATH; CELL PROTECTION; CELL STIMULATION; HUMAN; HUMAN CELL; PATHOGENESIS; PRIORITY JOURNAL; T CELL LYMPHOMA; UPREGULATION;

ANTIGENS, CD95; APOPTOSIS; CELL DEATH; FAS LIGAND PROTEIN; FLOW CYTOMETRY; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOMA, T-CELL; RECEPTORS, ANTIGEN, T-CELL; SEZARY SYNDROME; SKIN NEOPLASMS; T-LYMPHOCYTES; UP-REGULATION;

EID: 66249137475     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4631     Document Type: Article

References (43)

1. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768-3785 (Pubitemid 40656118)
2. Vonderheid EC, Bernengo MG, Burg G, et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002;46:95-106. (Pubitemid 34073484)
3. Dummer R, Asagoe K, Cozzio A, et al. Recent advances in cutaneous lymphomas. J Dermatol Sci 2007;48:157-167 (Pubitemid 350027784)
4. Hwang ST, Janik JE, Jaffe ES, Wilson WH. Mycosis fungoides and Sézary syndrome. Lancet 2008;371:945-957
5. Schulze-Bergkamen H, Krammer PH. Apoptosis in cancer-implications for therapy. Semin Oncol 2004;31:90-119.
6. Krammer PH, Arnold R, Lavrik IN. Life and death in peripheral T cells. Nat Rev Immunol 2007;7:532-542 (Pubitemid 46987784)
7. Lenardo MJ. Interleukin-2 programs mouse α β T lymphocytes for apoptosis. Nature 1991;353:858-861 (Pubitemid 21912642)
8. Krammer PH. CD95's deadly mission in the immune system. Nature 2000;407:789-795
9. Schmitz I, Weyd H, Krueger A, et al. Resistance of short term activated T cells to CD95-mediated apoptosis correlates with de novo protein synthesis of c-FLIPshort. J Immunol 2004;172:2194-2200 (Pubitemid 38182366)
10. Gulow K, Kaminski M, Darvas K, Suss D, Li-Weber M, Krammer PH. HIV-1 trans-activator of transcription substitutes for oxidative signaling in activation-induced T cell death. J Immunol 2005;174:5249-5260 (Pubitemid 40593163)
11. Brenner D, Golks A, Kiefer F, Krammer PH, Arnold R. Activation or suppression of NFnB by HPK1 determines sensitivity to activation-induced cell death. EMBO J 2005;24:4279-4290 (Pubitemid 41828903)
12. Ni X, Zhang C, Talpur R, Duvic M. Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas. J Invest Dermatol 2005;124:741-750 (Pubitemid 40489501)
13. Sprick MR, Weigand MA, Rieser E, et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000;12:599-609.
14. Krueger A, Fas SC, Giaisi M, et al. HTLV-1 Tax protects against CD95-mediated apoptosis by induction of the cellular FLICE-inhibitory protein (c-FLIP). Blood 2006;107:3933-3939
15. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002;296:550-553 (Pubitemid 34408678)
16. Diessenbacher P, Hupe M, Sprick MR, et al. NF-κB inhibition reveals differential mechanisms of TNF versus TRAIL-induced apoptosis upstream or at the level of caspase-8 activation independent of cIAP2. J Invest Dermatol 2008;128:1134-1147
17. Geserick P, Drewniok C, Hupe M, et al. Suppression of cFLIP is sufficient to sensitize human melanoma cells to T. Oncogene 2008;27:3211-3220
18. Gerin PA, Searle PF, Al Rubeai M. Production of retroviral vectors for gene therapy with the human packaging cell line FLYRD18. Biotechnol Prog 1999;15:941-948 (Pubitemid 29475635)
19. Baumann S, Dostert A, Novac N, et al. Glucocorticoids inhibit activation-induced cell death (AICD) via direct DNA-dependent repression of the CD95 ligand gene by a glucocorticoid receptor dimer. Blood 2005;106:617-625 (Pubitemid 40981259)
20. Kaminski M, Kiessling M, Suss D, Krammer PH, Gulow K. Novel role for mitochondria: protein kinase Cθ-dependent oxidative signaling organelles in activation-induced T-cell death. Mol Cell Biol 2007;27:3625-3639 (Pubitemid 46726173)
21. Oyarzo MP, Medeiros LJ, Atwell C, et al. c-FLIP confers resistance to FAS-mediated apoptosis in anaplastic large-cell lymphoma. Blood 2006;107:2544-2547 (Pubitemid 43345581)
22. Valnet-Rabier MB, Challier B, Thiebault S, et al. c-Flip protein expression in Burkitt's lymphomas is associated with a poor clinical outcome. Br J Haematol 2005;128:767-773 (Pubitemid 40444868)
23. Braun FK, Fecker LF, Schwarz C, et al. Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells. J Invest Dermatol 2007;127:2425-2437 (Pubitemid 47619746)
24. Contassot E, Kerl K, Roques S, et al. Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression. Blood 2008;111:4780-4787
25. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J. NF-κB signals induce the expression of c-FLIP. Mol Cell Biol 2001;21:5299-5305 (Pubitemid 32702435)
26. Golks A, Brenner D, Krammer PH, Lavrik IN. The c-FLIP-NH2 terminus (p22-FLIP) induces NF-κB activation. J Exp Med 2006;203:1295-1305 (Pubitemid 43736598)
27. Sors A, Jean-Louis F, Pellet C, et al. Down-regulating constitutive activation of the NF-κB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood 2006;107:2354-2363 (Pubitemid 43345555)
28. Nikolova M, Musette P, Bagot M, Boumsell L, Bensussan A. Engagement of ILT2/CD85j in Sezary syndrome cells inhibits their CD3/TCR signaling. Blood 2002;100:1019-1025
29. Fargnoli MC, Edelson RL, Berger CL, et al. Diminished TCR signaling in cutaneous T cell lymphoma is associated with decreased activities of Zap70, Syk and membrane-associated Csk. Leukemia 1997;11:1338-1346
30. Klemke CD, Goerdt S, Schrama D, Becker JC. New insights into the molecular biology and targeted therapy of cutaneous T-cell lymphomas. J Dtsch Dermatol Ges 2006;4:395-406.
31. Van Doorn R, Dijkman R, Vermeer MH, Starink TM, Willemze R, Tensen CP. A novel splice variant of the Fas gene in patients with cutaneous T-cell lymphoma. Cancer Res 2002;62:5389-5392
32. Zoi-Toli O, Vermeer MH, De Vries E, Van Beek P, Meijer CJ, Willemze R. Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL. Br J Dermatol 2000;143:313-319 (Pubitemid 30650398)
33. Wu J, Nihal M, Siddiqui J, Vonderheid EC, Wood GS. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation. J Invest Dermatol. Epub20 08 Oct 16.
34. Kurland JF, Kodym R, Story MD, Spurgers KB, McDonnell TJ, Meyn RE. NF-κB1 (p50) homodimers contribute to transcription of the bcl-2 oncogene. J Biol Chem 2001;276:45380-45386
35. Zhang CL, Kamarashev J, Qin JZ, Burg G, Dummer R, Dobbeling U. Expression of apoptosis regulators in cutaneous T-cell lymphoma (CTCL) cells. J Pathol 2003;200:249-254 (Pubitemid 36748034)
36. Poszepczynska E, Bagot M, Echchakir H, et al. Functional characterization of an IL-7-dependent CD4(+)CD8αα (+) Th3-type malignant cell line derived from a patient with a cutaneous T-cell lymphoma. Blood 2000;96:1056-1063
37. Qin JZ, Zhang CL, Kamarashev J, Dummer R, Burg G, Dobbeling U. Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells. Blood 2001;98:2778-2783
38. Mao X, Orchard G, Lillington DM, et al. BCL2 and JUNB abnormalities in primary cutaneous lymphomas. Br J Dermatol 2004;151:546-556 (Pubitemid 39330877)
39. Sommer VH, Clemmensen OJ, Nielsen O, et al. In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia 2004;18:1288-1295
40. Marzec M, Halasa K, Kasprzycka M, et al. Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells. Cancer Res 2008;68:1083-1091
41. Vermeer MH, Van Doorn R, Dijkman R, et al. Novel and highly recurrent chromosomal alterations in Sézary syndrome. Cancer Res 2008;68:2689-2698
42. Fantin VR, Loboda A, Paweletz CP, et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res 2008;68:3785-3794
43. Gerwien J, Nielsen M, Labuda T, et al. Cutting edge: TCR stimulation by antibody and bacterial superantigen induces Stat3 activation in human T cells. J Immunol 1999;163:1742-1745 (Pubitemid 29382169)